Answers from the Lab

Min Shi, M.D., Ph.D., explains recent updates to the B-cell lymphoblastic leukemia minimal residual disease flow cytometry assay. This test is used to identify minimal residual disease in patients with a previously confirmed diagnosis of B-cell lymphoblastic leukemia who have completed chemotherapy, immunotherapy, or bone marrow transplantation.

Show Notes

(00:45)
 Could you just provide our listeners with a little bit of information about you and your background?
 
 (01:00)
 The laboratory recently made some updates to this testing for minimal residual disease. Can you just give us a brief overview of that assay?
 
(03:22)
 So these patients go through these treatments, and at what point do they really need this testing, or when should it be considered by clinicians to perform it?
 
(05:18)
 What brought the laboratory to flow cytometry for this MRD test for this particular disease state? Why did we not choose those other methods?
 
(09:44)
 So hearing you talk about how this test is serving the entire patient population, how are these results for this minimal residual disease test used for patient care?
 


What is Answers from the Lab?

A Mayo Clinic curated podcast sharing Mayo Clinic knowledge and advancements on the state of testing, science, and people who are making it happen behind the scenes.